Anlon Healthcare Posts Strong Growth with 42.98% Consolidated Revenue Increase for FY26

Anlon Healthcare Posts Strong Growth with 42.98% Consolidated Revenue Increase for FY26​

Anlon Healthcare Limited, a leading manufacturer of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), announced its Audited Financial Results (Standalone and Consolidated) for the quarter and full year ended March 31, 2026. The company reported significant growth in revenue, profitability, and margins, driven by robust research and development execution and strategic capacity expansion.

Financial Performance Overview​

The financial results indicate strong year-over-year growth across key metrics, both in consolidated and standalone reports.

The consolidated figures highlight the following performance data:


For standalone figures, the results showed a robust performance:

Strategic Growth and Key Developments​

Anlon Healthcare reported several strategic and operational milestones during the year. The company completed the acquisition of Bizotic Lifescience, which is now a subsidiary, thereby strengthening its manufacturing platform and growth capabilities. Furthermore, Apiqo Organics continues to enhance backward integration and supply chain efficiency across its pharmaceutical intermediates and specialty chemical product lines.

Operational highlights included the continued development of three molecules for two global innovator companies under the CDMO business vertical. The company maintained its focus on expanding its presence across the pharmaceutical, nutraceutical, veterinary, and personal care sectors.

Management Perspective​

Punitkumar Rasadia, Chairman and Managing Director of Anlon Healthcare Limited, stated that FY26 marked a period of significant growth, combining strong financial performance with meaningful strategic progress.

He noted that the consolidated Total Income reached ₹172.22 Crores, marking a growth of 42.98% over FY25. EBITDA saw an increase of 47.55% to ₹47.77 Crores, while Profit After Tax grew by 41.77% to ₹29.09 Crores. This growth was attributed to expanding demand across the API and pharmaceutical intermediates portfolio, improved operational efficiencies, and disciplined execution.

The company further highlighted that it strengthened its manufacturing and integration capabilities through the acquisitions of Apiqo Organics and Bizotic Lifescience. These additions are key components of its long-term growth platform. The company also advanced its regulatory and innovation capabilities, conducting 21 DMF filings and pursuing ongoing CDMO projects for global innovator companies.

Rasadia pointed out that alongside its core pharmaceutical business, the company has successfully diversified into the Industrial & Fine Chemicals segment, which is showing encouraging traction and complements existing manufacturing capabilities and customer relationships.

About Anlon Healthcare Limited​

Incorporated in 2013 and headquartered in Rajkot, Gujarat, Anlon Healthcare Limited is a research-driven manufacturer specializing in high-purity advanced pharmaceutical intermediates and APIs. The company supplies essential building blocks for finished dosage formulations. Anlon Healthcare is noted as one of the few Indian manufacturers of key APIs like Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol, which are used for pain and inflammation management. Its product range serves multiple sectors, including pharmaceuticals, nutraceuticals, personal care, and animal health. With an installed capacity of 400 MTPA, four R&D centers, and a global presence across more than 15 countries, Anlon continues to advance health through innovation, quality, and sustainability.

AHCL Stock Price Movement​

Anlon Healthcare Limited shares slipped by 2.81% on Friday, closing the session out at ₹13.85. Trading volume for the day was robust, recording transactions across 10.07 million shares.